J2604 Insurance Policy Changes

Kevzara (sarilumab) (Revised)

This is a revised Humana Medicare Advantage prior authorization policy for Kevzara (sarilumab) effective January 1, 2026, with updates as of June 24, 2026. The policy establishes specific clinical criteria for coverage across three indications: moderate to severe rheumatoid arthritis (requires 2 prior therapy failures/contraindications), polymyalgia rheumatica (requires 1 prior corticosteroid therapy/contraindication), and polyarticular juvenile idiopathic arthritis in patients ≥63 kg (requires 2 prior therapy failures/contraindications). All Kevzara requests require prior authorization before dispensing.